Report
PHARMACEUTICALS KOL meeting on hemophilia: Hemlibra no. 1 but Mim-8 could be a serious challenger
We organised a KOL meeting with a specialist in hemophilia to discuss recent data on new drugs in development since some of them are closer and closer to the market. Our focus was on hemophilia A since it is the biggest market and where most drugs are in development. Unsurprisingly, this KOL continues to prefer Hemlibra (Roche) over exiting factor VIII. However, he explained that, since some patients would prefer to stay with "classic" factor VIII (whose efficacy and safety has been well established for many years), he highlighted that efanesoctocog alfa (Sanofi) should be a very interesting choice. Finally, he has a lot of questions regarding gene therapy and had some difficulties being fully convinced.
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Jean-Jacques Le Fur
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.